厄洛替尼联合放疗治疗老年晚期非小细胞肺癌的临床研究  

Clinical research of Erlotinib combined with radiotherapy in the treatment of elderly patients with advanced non-small cell lung cancer

作　　者：刘淑娟[1] 杨升峰[1] 孙京栋 

机构地区：[1]青岛市肿瘤医院,山东青岛266042

出　　处：《中国民康医学》2013年第8期4-5,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:观察厄洛替尼联合适形调强放疗治疗老年晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法:对21例老年晚期非小细胞肺癌患者给予厄洛替尼150mg/d口服治疗,直到疾病进展或出现不可耐受的毒副反应,同步应用适形调强放疗,评价其临床疗效、生活质量、中位生存期、疾病进展时间及毒副反应。结果:完全缓解3例,部分缓解7例,稳定7例,进展4例,全组有效率47.6%,疾病控制率80.9%,中位生存期10.6个月,1年生存率52.3%。主要不良反应是皮疹、腹泻和骨髓抑制,经对症处理后均可缓解。结论:厄洛替尼联合适形调强放疗对老年晚期非小细胞肺癌疗效较好,安全性高,对不能同步放化疗、一般状况较差的患者有可能更多获益。Objective： To observe the efficacy and adverse reactions of Erlotinib combined with radiotherapy in the treatment of elderly patients with advanced non - small cell lung cancer. Methods： 21 elderly patients with advanced non - small cell lung cancer were treated with erlotinib （ 150mg / d, oral）, until disease progression or intolerable toxicity, simultaneous application of conformal radiotherapy. Until disease progression or intolerable toxicity, simultaneous application of conformal radiotherapy. Then, evaluated the clinical efficacy, quality of life, the median survival time, time to progression and toxicity. Results ：3 cases of complete remission, partial remission in 7 cases, stable in 7 cases,progress in 4 cases, the whole group was 47.6% effective, disease control rate of 80.9%, the median survival of 10.6 months, 1 year survival rate 52.3%. The main adverse reactions are rash, diarrhea and bone marrow suppression, after symptomatic treatment can be alleviated. Conclusion： Erlotnib combined with conformal intensity modulated radiation therapy for elderly patients with advanced non - small cell lung cancer with good effect,high safety,and not concurrent chemoradiotherapy,poor general condi- tion of the patients are likely to benefit more.

关 键 词：厄洛替尼 适形调强放疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]